Recent developments highlight Amesite's product launches, revenue growth, market expansion, and regulatory compliance achievements primarily related to its NurseMagic™ platform.

• Amesite Inc. launched the NurseMagic™ Enterprise Tier to enhance healthcare documentation for mid- and large-scale providers [N1].
• The company reported 2.4x revenue growth for NurseMagic™ in Q3 2025 amid ongoing cost reductions [N2].
• Amesite launched a higher-priced Teams Plus+ tier for NurseMagic™ responding to increased demand from enterprises [N4].
• NurseMagic™ now meets HIPAA requirements for all users, supporting regulatory compliance [N5].
• The company expanded market reach with early adoption of NurseMagic™ non-clinical caregiver tool [N6].
• Amesite reported 1,000% growth in hospice documentation tool adoption with NurseMagic™ [N7].
• The company announced automated sales flow success for NurseMagic™ in healthcare markets [N8].
• Amesite's stock experienced significant intraday price increases, reflecting market interest [N3].

Amesite's recent product launches, including the Enterprise tier of NurseMagic™ with EMR compatibility, and reported strong revenue growth for NurseMagic™ indicate traction in the post-acute healthcare market. The company's ability to rapidly deploy solutions that meet regulatory requirements and deliver measurable workflow improvements supports adoption by healthcare enterprises. Expanding subscription tiers and growing user communities enhance brand recognition and market penetration. Strong liquidity ratios provide financial flexibility to support ongoing product development and sales efforts.

Amesite operates in a highly competitive healthcare software market with established EMR providers and new AI-focused entrants. The company reported a net loss and modest revenue as of June 30, 2026, indicating ongoing challenges in achieving profitability. Nasdaq listing compliance risks related to minimum stockholders' equity requirements pose potential operational uncertainties. The small size of the team may limit scalability. Regulatory complexity and the need to convince customers to adopt new technology-driven approaches present ongoing execution risks.

Amesite's moat derives from its specialized AI-powered healthcare software tailored for post-acute care, combining rapid deployment, practitioner-driven design, and robust regulatory compliance. Its portfolio of patents and trademarks, along with proprietary AI models trained on curated datasets, supports technological differentiation. The company's dual B2C and B2B approach, with a freemium model facilitating user adoption and enterprise scalability, builds network effects and customer references. However, the healthcare software market is competitive with established EMR vendors and emerging AI-first entrants, requiring continuous innovation and compliance to maintain differentiation.

• Nasdaq Listing Compliance Risk: The company received a deficiency letter for not meeting minimum stockholders' equity requirements but has submitted a plan and received extensions. Failure to maintain compliance could lead to delisting, reduced liquidity, and impaired ability to raise capital [S2].
• Competitive Market Environment: Amesite faces substantial competition from established EMR vendors, mid-market specialized providers, AI-first entrants, and niche clinical tool vendors. Maintaining differentiation and customer adoption requires continuous innovation and regulatory compliance [S1].
• Financial Performance and Profitability: The company reported a net loss of $3.1 million and modest revenue of $364,777 for fiscal 2026, indicating challenges in scaling revenue and achieving profitability [S1].
• Regulatory and Compliance Complexity: Operating in healthcare requires strict adherence to HIPAA, HITECH, CMS, and other federal and state regulations. Non-compliance risks include penalties, legal liability, and operational restrictions [S1].
• Small Workforce and Scalability: With only 5 full-time employees and 1 consultant, the company's limited human capital may constrain growth and operational scalability [S1].

• Amesite Inc. is a technology company focused on AI-powered solutions for enterprise and professionals, emphasizing the post-acute healthcare market [S1].
• The company operates two main product lines: NurseMagic™ and LynkMagic™ [S1].
• NurseMagic™ includes a B2B enterprise application and a B2C solution for individual healthcare professionals [S1].
• LynkMagic™ provides enterprise AI solutions for healthcare and related organizations [S1].
• NurseMagic™ supports documentation, workflow, compliance, and operational efficiency improvements [S1].
• The B2C NurseMagic™ app connects directly with nurses and caregivers, providing tools to reduce documentation time and support workflow [S1].
• The B2B NurseMagic™ solution serves healthcare businesses including home health, skilled nursing, hospice, and non-clinical segments [S1].
• NurseMagic™ is designed for fast, secure deployment and measurable value in demanding business environments [S1].
• Amesite launched a census-based Enterprise tier with EMR compatibility and automated interdisciplinary team reporting in fiscal 2026 [S1].
• The company secured its largest enterprise deployment serving approximately 2,700 patients [S1].
• NurseMagic™ has multiple subscription tiers, including free versions for individual users and scalable plans for enterprises [S1].
• The company emphasizes digital marketing, social media engagement, and partnerships with healthcare influencers to build NurseMagic™'s reputation and adoption [S1].
• Amesite has 5 full-time employees and 1 consultant as of June 30, 2026 [S1].
• The company holds fifteen U.S. patents including one covering its AI platform and has registered trademarks for AMESITE®, KEEP LEARNING®, and LEARNING COMMUNITY ENVIRONMENT®, with pending trademarks for NURSEMAGIC™ and LYNKMAGIC™ [S1].
• Amesite's technology platform is built for security, flexibility, and speed, using modern languages and frameworks with proprietary AI models trained on curated datasets [S1].
• The company prioritizes regulatory compliance with HIPAA, HITECH, CMS standards, and other federal and state healthcare regulations [S1].
• NurseMagic™ now meets HIPAA requirements for all users [N5].
• Amesite reported 2.4x revenue growth for NurseMagic™ in Q3 2025 amid ongoing cost reductions [N2].
• The company launched a higher-priced Teams Plus+ tier for NurseMagic™ responding to increased enterprise demand [N4].
• Amesite launched NurseMagic™ Enterprise Tier to enhance healthcare documentation for mid- and large-scale providers [N1].
• NurseMagic™ saw 1,000% growth in hospice documentation tool adoption [N7].
• The company expanded market reach with early adoption of NurseMagic™ non-clinical caregiver tool [N6].
• Amesite announced automated sales flow success for NurseMagic™ in healthcare markets [N8].
• The company closed a $3.6 million underwritten public offering of common stock in early 2025 [N3].
• Amesite's stock experienced significant intraday price increases on multiple occasions in early 2025 [N3, N8].
• Financial figures as of June 30, 2026 include cash and equivalents of $2,298,809, current assets of $2,412,984, current liabilities of $375,918, revenue of $364,777, net loss of $3,095,838, and basic and diluted EPS of -$0.63 [S1].
• Liquidity ratios as of June 30, 2026 show a current ratio of 6.42 and a cash ratio of 6.12, indicating strong short-term liquidity [S1].
• The company faces Nasdaq listing compliance risks related to minimum stockholders' equity requirements but has submitted plans and received extensions to maintain listing [S2].